Key result
Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) treatment for acute myocardial infarction was complicated by vasculitis in 2.4% (6 of 253) of patients.
Why the study?
Does intravenous APSAC cause vasculitis in patients with acute myocardial infarction?
Observational (n=253)
Does intravenous APSAC cause vasculitis in patients with acute myocardial infarction?
Intravenous APSAC treatment for acute myocardial infarction can be complicated by vasculitis, though patients in this cohort recovered spontaneously.
Answers are grounded in this paper and cite their sources.
May warrant monitoring for vasculitis with APSAC in AMI; hypothesis-generating and requires prospective validation.
Vasculitis developed in six of 253 patients treated with intravenous anisoylated plasminogen streptokinase activator complex (APSAC) after acute myocardial infarction. All patients recovered spontaneously with no evidence of renal impairment and no long term sequelae. Although leucocytoclastic vasculitis and serum sickness have been reported after streptokinase treatment, such allergic reactions have not been described as a complication of other thrombolytic agents.
No takes yet. Share an insight, caveat, or question.
Bucknall et al. (1988) conducted an observational in Acute myocardial infarction (n=253). Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) was evaluated on Vasculitis. Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) treatment for acute myocardial infarction was complicated by vasculitis in 2.4% (6 of 253) of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: